Featured Research

from universities, journals, and other organizations

Denosumab delayed time to first skeletal-related side effect

Date:
December 10, 2010
Source:
American Association for Cancer Research
Summary:
For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to new results.

For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

Related Articles


"The average life expectancy of patients with metastatic breast cancer is approximately 2.5 years, so if you can prolong the time without a skeletal-related event by five months, you are substantially benefiting the patient," said Alison T. Stopeck, M.D., associate professor of medicine and director of the Clinical Breast Cancer Program at the Arizona Cancer Center, University of Arizona, Tucson.

The Food and Drug Administration approved denosumab, sold by Amgen as XGEVA starting Nov. 18, 2010, for the prevention of skeletal-related events in patients with bone metastases from solid tumors.

Previous results from this Phase III trial indicated that denosumab was superior to zoledronic acid in delaying the time to first on-study, skeletal-related side effects, such as fracture, radiation to bone, surgery to bone or spinal cord compression in patients with breast cancer and bone metastases. These results detail an additional four months of blinded treatment.

Stopeck and colleagues randomized 2,046 patients with advanced breast cancer to receive either 120 mg of subcutaneous denosumab or 4 mg of intravenous zoledronic acid every four weeks. Both of these drugs inhibit osteoclasts, or the cells that break down bone, therefore, all patients took calcium and vitamin D daily.

Denosumab was better at delaying the time to first on-study, skeletal-related event by 18 percent and the time to first and subsequent event by 22 percent. The median time to first on-study, skeletal-related event was five months longer for the denosumab group compared to the zoledronic acid group.

Overall survival and disease progression was similar for both groups. Rates of side effects were 96.2 percent for those taking denosumab and 97.4 percent for those taking zoledronic acid. Jaw osteonecrosis occurred in 2.5 percent of patients taking denosumab and 1.8 percent of those taking zoledronic acid.

Stopeck thinks these results will be practice changing. "We now have an alternative to zoledronic acid that is more convenient, less toxic and more effective for patients with bone metastases," she said.


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "Denosumab delayed time to first skeletal-related side effect." ScienceDaily. ScienceDaily, 10 December 2010. <www.sciencedaily.com/releases/2010/12/101210154524.htm>.
American Association for Cancer Research. (2010, December 10). Denosumab delayed time to first skeletal-related side effect. ScienceDaily. Retrieved October 26, 2014 from www.sciencedaily.com/releases/2010/12/101210154524.htm
American Association for Cancer Research. "Denosumab delayed time to first skeletal-related side effect." ScienceDaily. www.sciencedaily.com/releases/2010/12/101210154524.htm (accessed October 26, 2014).

Share This



More Health & Medicine News

Sunday, October 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) — An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
Toxin-Packed Stem Cells Used To Kill Cancer

Toxin-Packed Stem Cells Used To Kill Cancer

Newsy (Oct. 25, 2014) — A Harvard University Research Team created genetically engineered stem cells that are able to kill cancer cells, while leaving other cells unharmed. Video provided by Newsy
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins